Knee Rheumatoid Arthritis News-Medical.net A newer approach is to use biological agents. TNF inhibitors were the first licensed biological agents including etanercept, infliximab, adalimumab and certolizumab. This was followed by monoclonal antibodies like abatacept, rituximab, and tocilizumab. |
